Renal ciliopathies: promising drug targets and prospects for clinical trials

References

• Reiter JF, Leroux MR. Genes and molecular pathways underpinning ciliopathies. Nat Rev Mol Cell Biol. 2017 Sep;18(9):533–547.
   PubMed Web of Science ®Google Scholar
• Sonnen KF, Schermelleh L, Leonhardt H, et al. 3D-structured illumination microscopy provides novel insight into architecture of human centrosomes. Biol Open. 2012 Oct 15;1(10):965–976. DOI:10.1242/bio.20122337
   PubMed Web of Science ®Google Scholar
• Andersen JS, Wilkinson CJ, Mayor T, et al. Proteomic characterization of the human centrosome by protein correlation profiling. Nature. 2003 Dec 04;426(6966):570–574. DOI:10.1038/nature02166
   PubMed Web of Science ®Google Scholar
• Cajanek L, Nigg EA. Cep164 triggers ciliogenesis by recruiting Tau tubulin kinase 2 to the mother centriole. Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):E2841–50. DOI:10.1073/pnas.1401777111
   PubMed Web of Science ®Google Scholar
• Yang, Yang TT, Chong WM, et al. Super-resolution architecture of mammalian centriole distal appendages reveals distinct blade and matrix functional components. Nat Commun. 2018;9(1). DOI:10.1038/s41467-018-04469-1
   Google Scholar
• Shi X, Garcia G 3rd, Van De Weghe JC, et al. Super-resolution microscopy reveals that disruption of ciliary transition-zone architecture causes Joubert syndrome. Nat Cell Biol. 2017 Oct;19(10):1178–1188.
   PubMed Web of Science ®Google Scholar
• Reiter JF, Blacque OE, Leroux MR. The base of the cilium: roles for transition fibres and the transition zone in ciliary formation, maintenance and compartmentalization. EMBO Rep. 2012 Jun 29;13(7):608–618. DOI:10.1038/embor.2012.73
   PubMed Web of Science ®Google Scholar
• Hu Q, Milenkovic L, Jin H, et al. A septin diffusion barrier at the base of the primary cilium maintains ciliary membrane protein distribution. Science. 2010 Jul;329(5990):436–439.
   PubMed Web of Science ®Google Scholar
• Kee HL, Dishinger JF, Blasius TL, et al. A size-exclusion permeability barrier and nucleoporins characterize a ciliary pore complex that regulates transport into cilia. Nat Cell Biol. 2012 Mar;14(4):431–437.
   PubMed Web of Science ®Google Scholar
• Yang TT, Su J, Wang WJ, et al. Superresolution pattern recognition reveals the architectural map of the ciliary transition zone. Sci Rep. 2015 Sep 14;5(1):14096. DOI:10.1038/srep14096
   PubMedGoogle Scholar
• Nachury MV, Loktev AV, Zhang Q, et al. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. Cell. 2007 Jun 15;129(6):1201–1213. DOI:10.1016/j.cell.2007.03.053
   PubMed Web of Science ®Google Scholar
• Nakayama K, Katoh Y. Ciliary protein trafficking mediated by IFT and BBSome complexes with the aid of kinesin-2 and dynein-2 motors. J Biochem. 2018 Mar 1;163(3):155–164. DOI:10.1093/jb/mvx087
   PubMed Web of Science ®Google Scholar
• Czarnecki PG, Shah JV. The ciliary transition zone: from morphology and molecules to medicine. Trends Cell Biol. 2012 Apr;22(4):201–210.
   PubMed Web of Science ®Google Scholar
• Alkanderi S, Molinari E, Shaheen R, et al. ARL3 mutations cause Joubert syndrome by disrupting ciliary protein composition. Am J Hum Genet. 2018 Oct 4;103(4):612–620. DOI:10.1016/j.ajhg.2018.08.015
   PubMed Web of Science ®Google Scholar
• Smith CEL, Lake AVR, Johnson CA. Primary cilia, ciliogenesis and the actin cytoskeleton: a little less resorption, a little more actin please. Front Cell Dev Biol. 2020;8:622822.
   PubMed Web of Science ®Google Scholar
• Gigante ED, Caspary T. Signaling in the primary cilium through the lens of the Hedgehog pathway. Wiley Interdiscip Rev Dev Biol. 2020 Nov;9(6):e377.
   PubMed Web of Science ®Google Scholar
• Breslow DK, Hoogendoorn S, Kopp AR, et al. A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet. 2018 Mar;50(3):460–471. DOI:10.1038/s41588-018-0054-7
   PubMed Web of Science ®Google Scholar
• Hynes AM, Giles RH, Srivastava S, et al. Murine Joubert syndrome reveals Hedgehog signaling defects as a potential therapeutic target for nephronophthisis. P Natl Acad Sci USA. 2014 Jul 8;111(27):9893–9898. DOI:10.1073/pnas.1322373111
   PubMed Web of Science ®Google Scholar
• Attanasio M, Uhlenhaut NH, Sousa VH, et al. Loss of GLIS2 causes nephronophthisis in humans and mice by increased apoptosis and fibrosis. Nat Genet. 2007 Aug;39(8):1018–1024.
   PubMed Web of Science ®Google Scholar
• Anvarian Z, Mykytyn K, Mukhopadhyay S, et al. Cellular signalling by primary cilia in development, organ function and disease. Nat rev Nephrol. 2019 Apr;15(4):199–219.
   PubMed Web of Science ®Google Scholar
• Fischer E, Legue E, Doyen A, et al. Defective planar cell polarity in polycystic kidney disease. Nat Genet. 2006 Jan;38(1):21–23.
   PubMed Web of Science ®Google Scholar
• Lancaster MA, Louie CM, Silhavy JL, et al. Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy. Nat Med. 2009 Sep;15(9):1046–1054.
   PubMed Web of Science ®Google Scholar
• Stokman MF, Saunier S, Benmerah A. Renal ciliopathies: sorting out therapeutic approaches for nephronophthisis. Front Cell Dev Biol. 2021;9:653138.
   PubMed Web of Science ®Google Scholar
• Molinari E, Sayer JA. Emerging treatments and personalised medicine for ciliopathies associated with cystic kidney disease. Expert Opin Orphan Drugs. 2017;5(10):785–798.
   Web of Science ®Google Scholar
• Lienkamp S, Ganner A, Walz G. Inversin, Wnt signaling and primary cilia. Differentiation. 2012 Feb;83(2):S49–55.
   PubMed Web of Science ®Google Scholar
• Boehlke C, Kotsis F, Patel V, et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol. 2010 Nov;12(11):1115–1122.
   PubMed Web of Science ®Google Scholar
• Gattone VH, Sinders RM, Hornberger TA, et al. Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis. Kidney Int. 2009 Jul;76(2):178–182.
   PubMed Web of Science ®Google Scholar
• Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han : SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transpl. 2006 Mar;21(3):598–604.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Marshall WF. Ciliogenesis: building the cell’s antenna. Nat Rev Mol Cell Biol. 2011 Apr;12(4):222–234.
   PubMed Web of Science ®Google Scholar
• Slaats GG, Ghosh AK, Falke LL, et al. Nephronophthisis-associated CEP164 regulates cell cycle progression, apoptosis and epithelial-to-mesenchymal transition. PLoS Genet. 2014 Oct;10(10):e1004594.
   PubMed Web of Science ®Google Scholar
• Sivasubramaniam S, Sun X, Pan YR, et al. Cep164 is a mediator protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and CHK1. Genes Dev. 2008 Mar 01;22(5):587–600. DOI:10.1101/gad.1627708
   PubMed Web of Science ®Google Scholar
• Bachmann-Gagescu R, Neuhauss SC. The photoreceptor cilium and its diseases. Curr Opin Genet Dev. 2019 Jun;56:22–33.
   PubMed Web of Science ®Google Scholar
• May-Simera H. The sensory antennae in the eye. Prog Retin Eye Res. 2017;60:144–180. DOI:10.1016/j.preteyeres.2017.05.001
   PubMedGoogle Scholar
• Jenkins PM, McEwen DP, Martens JR. Olfactory cilia: linking sensory cilia function and human disease. Chem Senses. 2009 Jun;34(5):451–464.
   PubMed Web of Science ®Google Scholar
• Mitchison HM, Valente EM. Motile and non-motile cilia in human pathology: from function to phenotypes. J Pathol. 2017 Jan;241(2):294–309.
   PubMed Web of Science ®Google Scholar
• Little RB, Norris DP. Right, left and cilia: How asymmetry is established. Semin Cell Dev Biol. 2021 Feb;110:11–18.
   PubMed Web of Science ®Google Scholar
• Wheway G, Schmidts M, Mans DA, et al. An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. Nat Cell Biol. 2015 Aug;17(8):1074–1087.
   PubMed Web of Science ®Google Scholar
• McConnachie DJ, Stow JL, Mallett AJ. Ciliopathies and the Kidney: A Review. Am J Kidney Dis. 2021 Mar;77(3):410–419.
   PubMed Web of Science ®Google Scholar
• Ciliopathy Alliance. 2020. Accessed 01 05 2023. Available from: https://ciliopathyalliance.org/
   Google Scholar
• Devlin LA, Sayer JA. Renal ciliopathies. Curr Opin Genet Dev. 2019 Jun;56:49–60.
   PubMed Web of Science ®Google Scholar
• Barroso-Gil M, Olinger E, Sayer JA. Molecular genetics of renal ciliopathies. Biochem Soc Trans. 2021 Jun 30;49(3):1205–1220. DOI:10.1042/BST20200791
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019 Mar 2;393(10174):919–935. DOI:10.1016/S0140-6736(18)32782-X
   PubMed Web of Science ®Google Scholar
• Lanktree MB, Haghighi A, Guiard E, et al. Prevalence estimates of polycystic kidney and liver disease by population sequencing. J Am Soc Nephrol. 2018 Oct;29(10):2593–2600.
   PubMed Web of Science ®Google Scholar
• Lanktree MB, Haghighi A, di Bari I, et al. Insights into autosomal dominant polycystic kidney disease from genetic studies. Clin J Am Soc Nephrol. 2021 May 8;16(5):790–799. DOI:10.2215/CJN.02320220
   PubMed Web of Science ®Google Scholar
• Duong Phu M, Bross S, Burkhalter MD, et al. Limitations and opportunities in the pharmacotherapy of ciliopathies. Pharmacol Ther. 2021 Sep;225:107841.
   PubMed Web of Science ®Google Scholar
• Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Bio. 2010 Nov 15;191(4):701–710. DOI:10.1083/jcb.201006173
   PubMed Web of Science ®Google Scholar
• Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007 Jul;18(7):2143–2160.
   PubMed Web of Science ®Google Scholar
• Su Q, Hu F, Ge X, et al. Structure of the human PKD1-PKD2 complex. Science. 2018 Sep 7;361(6406). DOI:10.1126/science.aat9819
   Web of Science ®Google Scholar
• Ta CM, Vien TN, Ng LCT, et al. Structure and function of polycystin channels in primary cilia. Cell Signal. 2020 Aug;72:109626.
   PubMed Web of Science ®Google Scholar
• Wang SX, Zhang JJ, Nauli SM, et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol. 2007 Apr;27(8):3241–3252.
   PubMed Web of Science ®Google Scholar
• Delling M, Indzhykulian AA, Liu X, et al. Primary cilia are not calcium-responsive mechanosensors. Nature. 2016 Mar 31;531(7596):656–660. DOI:10.1038/nature17426
   PubMed Web of Science ®Google Scholar
• Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018 Dec 6;4(1):50. DOI:10.1038/s41572-018-0047-y
   PubMed Web of Science ®Google Scholar
• Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan;26(1):160–172.
   PubMed Web of Science ®Google Scholar
• McEwan P, Bennett Wilton H, Ong ACM, et al. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD outcomes model. BMC Nephrol. 2018 Feb 13;19(1):37. DOI:10.1186/s12882-017-0804-2
   PubMedGoogle Scholar
• Edwards ME, Blais JD, Czerwiec FS, et al. Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease. Clin Kidney J. 2019 Feb;12(1):71–77.
   PubMed Web of Science ®Google Scholar
• Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009 Apr;75(8):848–855.
   PubMed Web of Science ®Google Scholar
• Qian F, Germino GG. “Mistakes Happen”: Somatic mutation and disease. Am J Hum Genet. 1997 Nov;61(5):1000–1005.
   PubMed Web of Science ®Google Scholar
• Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int. 2011 Oct;80(7):768–776.
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease. Am J Hum Genet. 2018 May 3;102(5):832–844. DOI:10.1016/j.ajhg.2018.03.013
   PubMed Web of Science ®Google Scholar
• Huynh VT, Audrezet MP, Sayer JA, et al. Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. Kidney Int. 2020 Aug;98(2):476–487.
   PubMed Web of Science ®Google Scholar
• Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB , encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet. 2016 Jun 2;98(6):1193–1207. DOI:10.1016/j.ajhg.2016.05.004
   PubMed Web of Science ®Google Scholar
• Besse W, Choi J, Ahram D, et al. A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. Hum Mutat. 2018 Mar;39(3):378–382.
   PubMed Web of Science ®Google Scholar
• Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. J Clin Invest. 2017 Sep 1;127(9):3558. DOI:10.1172/JCI96729
   PubMed Web of Science ®Google Scholar
• Besse W, Chang AR, Luo JZ, et al. ALG9 mutation carriers develop kidney and liver cysts. J Am Soc Nephrol. 2019 Nov;30(11):2091–2102.
   PubMed Web of Science ®Google Scholar
• Li A, Davila S, Furu L, et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet. 2003 Mar;72(3):691–703.
   PubMed Web of Science ®Google Scholar
• Bolar NA, Golzio C, Zivna M, et al. Heterozygous loss-of-function SEC61A1 mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. Am J Hum Genet. 2016 Jul 7;99(1):174–187. DOI:10.1016/j.ajhg.2016.05.028
   PubMed Web of Science ®Google Scholar
• Senum SR, Li Y(M, Benson KA, et al. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. Am J Hum Genet. 2022 Jan 6;109(1):136–156. DOI:10.1016/j.ajhg.2021.11.016
   PubMed Web of Science ®Google Scholar
• Devuyst O, Knoers NV, Remuzzi G, et al. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet. 2014 May 24;383(9931):1844–1859. DOI:10.1016/S0140-6736(14)60659-0
   PubMed Web of Science ®Google Scholar
• Burgmaier K, Kilian S, Bammens B, et al. Clinical courses and complications of young adults with Autosomal Recessive Polycystic Kidney Disease (ARPKD). Sci Rep. 2019 May 28;9(1):7919. DOI:10.1038/s41598-019-43488-w
   PubMedGoogle Scholar
• Goetz SC, Bangs F, Barrington CL, et al. The Meckel syndrome- associated protein MKS1 functionally interacts with components of the BBSome and IFT complexes to mediate ciliary trafficking and hedgehog signaling. PLoS ONE. 2017;12(3):e0173399. DOI:10.1371/journal.pone.0173399
   PubMed Web of Science ®Google Scholar
• Molinari E, Srivastava S, Dewhurst RM, et al. Use of patient derived urine renal epithelial cells to confirm pathogenicity of PKHD1 alleles. BMC Nephrol. 2020 Oct 15;21(1):435. DOI:10.1186/s12882-020-02094-z
   PubMed Web of Science ®Google Scholar
• Ward CJ, Hogan MC, Rossetti S, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002 Mar;30(3):259–269.
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr., Avner ED. Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD). Cell Tissue Res. 2006 Dec;326(3):671–685.
   PubMed Web of Science ®Google Scholar
• Lu H, Galeano MCR, Ott E, et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet. 2017 Jul;49(7):1025–1034.
   PubMed Web of Science ®Google Scholar
• Devane J, Ott E, Olinger EG, et al. Progressive liver, kidney, and heart degeneration in children and adults affected by TULP3 mutations. Am J Hum Genet. 2022 May 5;109(5):928–943. DOI:10.1016/j.ajhg.2022.03.015
   PubMed Web of Science ®Google Scholar
• Srivastava S, Molinari E, Raman S, et al. Many genes-one disease? Genetics of Nephronophthisis (NPHP) and NPHP-associated disorders. Front Pediatr. 2017 ;5:287.
   PubMed Web of Science ®Google Scholar
• Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol. 2009 Jan;20(1):23–35.
   PubMed Web of Science ®Google Scholar
• Snoek R, van Setten J, Keating BJ, et al. NPHP1 (Nephrocystin-1) Gene deletions cause adult-onset ESRD. J Am Soc Nephrol. 2018 Jun;29(6):1772–1779.
   PubMed Web of Science ®Google Scholar
• Hoefele J, Nayir A, Chaki M, et al. Pseudodominant inheritance of nephronophthisis caused by a homozygous NPHP1 deletion. Pediatr Nephrol. 2011 Jun;26(6):967–971.
   PubMed Web of Science ®Google Scholar
• Salomon R, Saunier S, Niaudet PN. Nephronophthisis. Pediatr Nephrol. 2009 Dec;24(12):2333–2344.
   PubMed Web of Science ®Google Scholar
• Chaki M, Airik R, Ghosh AK, et al. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell. 2012 Aug 3;150(3):533–548. DOI:10.1016/j.cell.2012.06.028
   PubMed Web of Science ®Google Scholar
• Otto EA, Schermer B, Obara T, et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet. 2003 Aug;34(4):413–420.
   PubMed Web of Science ®Google Scholar
• Tory K, Rousset-Rouviere C, Gubler MC, et al. Mutations of NPHP2 and NPHP3 in infantile nephronophthisis. Kidney Int. 2009 Apr;75(8):839–847.
   PubMed Web of Science ®Google Scholar
• Failler M, Gee HY, Krug P, et al. Mutations of CEP83 cause infantile nephronophthisis and intellectual disability. Am J Hum Genet. 2014 Jun 5;94(6):905–914. DOI:10.1016/j.ajhg.2014.05.002
   PubMed Web of Science ®Google Scholar
• Otto EA, Trapp ML, Schultheiss UT, et al. NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. J Am Soc Nephrol. 2008 Mar;19(3):587–592.
   PubMed Web of Science ®Google Scholar
• Olbrich H, Fliegauf M, Hoefele J, et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet. 2003 Aug;34(4):455–459.
   PubMed Web of Science ®Google Scholar
• Georges B, Cosyns JP, Dahan K, et al. Late-onset renal failure in Senior-Loken syndrome. Am J Kidney Dis. 2000 Dec;36(6):1271–1275.
   PubMed Web of Science ®Google Scholar
• Macia MS, Halbritter J, Delous M, et al. Mutations in MAPKBP1 cause juvenile or late-onset cilia-independent nephronophthisis. Am J Hum Genet. 2017 Feb 2;100(2):372. DOI:10.1016/j.ajhg.2017.01.025
   PubMed Web of Science ®Google Scholar
• Shamseldin HE, Shaheen R, Ewida N, et al. The morbid genome of ciliopathies: an update. Genet Med. 2020 Jun;22(6):1051–1060.
   PubMed Web of Science ®Google Scholar
• Braun DA, Hildebrandt F. Ciliopathies. Cold Spring Harb Perspect Biol. 2017 Mar 1;9(3):a028191. DOI:10.1101/cshperspect.a028191
   PubMed Web of Science ®Google Scholar
• Parisi M, Glass I. Joubert syndrome. In: Adam M, Mirzaa GM, and Pagon RA, editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle; 1993-2023. https://www.ncbi.nlm.nih.gov/books/NBK1325/
   Google Scholar
• Brancati F, Dallapiccola B, Valente EM. Joubert syndrome and related disorders. Orphanet J Rare Dis. 2010 Jul;5:20.
   PubMed Web of Science ®Google Scholar
• Parisi MA. The molecular genetics of Joubert syndrome and related ciliopathies: The challenges of genetic and phenotypic heterogeneity. Trans Sci Rare Dis. 2019 Jul 4;4(1–2):25–49.
   PubMedGoogle Scholar
• Radha Rama Devi A, Naushad SM, Lingappa L. Clinical and molecular diagnosis of Joubert syndrome and related disorders. Pediatr Neurol. 2020 May;106:43–49.
   PubMed Web of Science ®Google Scholar
• Forsythe E, Kenny J, Bacchelli C, et al. Managing Bardet-Biedl syndrome-now and in the future. Front Pediatr. 2018 ;6:23.
   PubMed Web of Science ®Google Scholar
• Maria M, Lamers IJ, Schmidts M, et al. Genetic and clinical characterization of Pakistani families with Bardet-Biedl syndrome extends the genetic and phenotypic spectrum. Sci Rep. 2016 Oct 06;6:34764.
   PubMed Web of Science ®Google Scholar
• Beales PL, Elcioglu N, Woolf AS, et al. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999 Jun;36(6):437–446.
   PubMed Web of Science ®Google Scholar
• Putoux A, Attie-Bitach T, Martinovic J, et al. Phenotypic variability of Bardet-Biedl syndrome: focusing on the kidney. Pediatr Nephrol. 2012 Jan;27(1):7–15.
   PubMed Web of Science ®Google Scholar
• Forsythe E, Sparks K, Best S, et al. Risk factors for severe renal disease in bardet-biedl syndrome. J Am Soc Nephrol. 2017 Mar;28(3):963–970.
   PubMed Web of Science ®Google Scholar
• Alliance C. Ciliopathy alliance: bardet-biedl syndrome. 2020 [01 Mar 2023] Available from: https://ciliopathyalliance.org/ciliopathies
   Google Scholar
• Barbelanne M, Hossain D, Chan DP, et al. Nephrocystin proteins NPHP5 and Cep290 regulate BBSome integrity, ciliary trafficking and cargo delivery. Hum Mol Genet. 2015 Apr 15;24(8):2185–2200.
   PubMed Web of Science ®Google Scholar
• UK B What is bardet biedl syndrome. 2020 [01 Mar 2023] Available from: https://bbsuk.org.uk/about-bbs-uk/bardet-biedl-syndrome/
   Google Scholar
• Seo S, Baye LM, Schulz NP, et al. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1488–1493. DOI:10.1073/pnas.0910268107
   PubMed Web of Science ®Google Scholar
• Otto EA, Loeys B, Khanna H, et al. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. Nat Genet. 2005 Mar;37(3):282–288.
   PubMed Web of Science ®Google Scholar
• Luo F, Tao YH. Nephronophthisis: A review of genotype-phenotype correlation. Nephrology (Carlton). 2018 Oct;23(10):904–911.
   PubMed Web of Science ®Google Scholar
• Hartill V, Szymanska K, Sharif SM, et al. Meckel-Gruber Syndrome: An Update on Diagnosis, Clinical Management, and Research Advances. Front Pediatr. 2017 ;5:244.
   PubMed Web of Science ®Google Scholar
• Humbert MC, Weihbrecht K, Searby CC, et al. ARL13B, PDE6D, and CEP164 form a functional network for INPP5E ciliary targeting. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19691–19696.
   PubMed Web of Science ®Google Scholar
• Field M, Scheffer IE, Gill D, et al. Expanding the molecular basis and phenotypic spectrum of X-linked Joubert syndrome associated with OFD1 mutations. Eur J Hum Genet. 2012 Jul;20(7):806–809.
   PubMed Web of Science ®Google Scholar
• Wheway G, Mitchison HM, Genomics England Research C. Opportunities and Challenges for Molecular Understanding of Ciliopathies-The 100,000 Genomes Project. Front Genet. 2019;10:127.
   PubMed Web of Science ®Google Scholar
• Rafferty KA Jr., Sherwin RW. The length of secondary chromosomal constrictions in normal individuals and in a nucleolar mutant of Xenopus laevis. Cytogenetics. 1969;8(6):427–438.
   PubMedGoogle Scholar
• Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977 Jul;36(1):59–74.
   PubMedGoogle Scholar
• Perantoni A, Berman JJ. Properties of Wilms’ tumor line (TuWi) and pig kidney line (LLC-PK1) typical of normal kidney tubular epithelium. In Vitro. 1979 Jun;15(6):446–454.
   PubMedGoogle Scholar
• Rauchman MI, Nigam SK, Delpire E, et al. An osmotically tolerant inner medullary collecting duct cell line from an SV40 transgenic mouse. Am J physiol. 1993 Sep;265(3 Pt 2):F416–24.
   PubMedGoogle Scholar
• Gaush CR, Hard WL, Smith TF. Characterization of an established line of canine kidney cells (MDCK). Proc Soc Exp Biol Med. 1966 Jul;122(3):931–935.
   PubMed Web of Science ®Google Scholar
• Molinari E, Decker E, Mabillard H, et al. Human urine-derived renal epithelial cells provide insights into kidney-specific alternate splicing variants. Eur J Hum Genet. 2018 Dec;26(12):1791–1796.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Ramsbottom SA, Molinari E, et al. A human patient-derived cellular model of Joubert syndrome reveals ciliary defects which can be rescued with targeted therapies. Hum Mol Genet. 2017;26(23):4657–4667.
   Web of Science ®Google Scholar
• Forbes TA, Howden SE, Lawlor K, et al. Patient-iPSC-derived kidney organoids show functional validation of a ciliopathic renal phenotype and reveal underlying pathogenetic mechanisms. Am J Hum Genet. 2018 May 3;102(5):816–831.
   PubMed Web of Science ®Google Scholar
• Schutgens F, Rookmaaker MB, Margaritis T, et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat Biotechnol. 2019 Mar;37(3):303–313.
   PubMed Web of Science ®Google Scholar
• Kuraoka S, Tanigawa S, Taguchi A, et al. PKD1-dependent renal cystogenesis in human induced pluripotent stem cell-derived ureteric bud/collecting duct organoids. J Am Soc Nephrol. 2020 Oct;31(10):2355–2371.
   PubMed Web of Science ®Google Scholar
• Yousef Yengej FA, Jansen J, Rookmaaker MB, et al. Kidney organoids and tubuloids. Cells. 2020 May 26;9(6):1326.
   PubMed Web of Science ®Google Scholar
• Uchimura K, Wu H, Yoshimura Y, et al. Human pluripotent stem cell-derived kidney organoids with improved collecting duct maturation and injury modeling. Cell Rep. 2020 Dec 15;33(11):108514. DOI:10.1016/j.celrep.2020.108514
   PubMed Web of Science ®Google Scholar
• Cruz NM, Song X, Czerniecki SM, et al. Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease. Nat Mater. 2017 Nov;16(11):1112–1119.
   PubMed Web of Science ®Google Scholar
• Low JH, Li P, Chew EGY, et al. Generation of human PSC-derived kidney organoids with patterned nephron segments and a de novo vascular network. Cell Stem Cell. 2019 Sep 5;25(3):373–387 e9. DOI:10.1016/j.stem.2019.06.009
   PubMed Web of Science ®Google Scholar
• Steichen C, Giraud S, Hauet T. Combining kidney organoids and genome editing technologies for a better understanding of physiopathological mechanisms of renal diseases: state of the art. Front Med. 2020;7:10.
   PubMed Web of Science ®Google Scholar
• Ashammakhi N, Wesseling-Perry K, Hasan A, et al. Kidney-on-a-chip: untapped opportunities. Kidney Int. 2018 Dec;94(6):1073–1086.
   PubMed Web of Science ®Google Scholar
• Molinari E, Ramsbottom SA, Sammut V, et al. Using zebrafish to study the function of nephronophthisis and related ciliopathy genes. F1000Res. 2018;7:1133.
   PubMedGoogle Scholar
• Nagao S, Yamaguchi T. Review of the use of animal models of human polycystic kidney disease for the evaluation of experimental therapeutic modalities. J Clin Med. 2023 Jan 14;12(2):668.
   PubMed Web of Science ®Google Scholar
• Nagao S, Kugita M, Yoshihara D, et al. Animal models for human polycystic kidney disease. Exp Anim. 2012;61(5):477–488.
   PubMed Web of Science ®Google Scholar
• Richards T, Modarage K, Malik SA, et al. The cellular pathways and potential therapeutics of Polycystic kidney disease. Biochem Soc Trans. 2021 Jun 30;49(3):1171–1188.
   PubMed Web of Science ®Google Scholar
• Mansour SG, Puthumana J, Coca SG, et al. Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review. BMC Nephrol. 2017 Feb 20;18(1):72.
   PubMedGoogle Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20;367(25):2407–2418.
   PubMed Web of Science ®Google Scholar
• Liebau MC, Hartung EA, Perrone RD. Perspectives on drug development in autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol. 2022 Oct;17(10):1551–1554.
   PubMed Web of Science ®Google Scholar
• Wang X, Gattone V 2nd, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005 Apr;16(4):846–851.
   PubMed Web of Science ®Google Scholar
• Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014 May;349(2):258–267.
   PubMed Web of Science ®Google Scholar
• Hopp K, Hommerding CJ, Wang X, et al. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol. 2015 Jan;26(1):39–47.
   PubMed Web of Science ®Google Scholar
• Di Mise A, Wang X, Ye H, et al. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J. 2021 Oct;35(10):e21874.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen F, Wang J, et al. Two novel homozygous mutations in NPHP1 lead to late onset end-stage renal disease: a case report of an adult nephronophthisis in a Chinese intermarriage family. BMC Nephrol. 2019 May 16;20(1):173.
   PubMedGoogle Scholar
• Yang BX, Sonawane ND, Zhao D, et al. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008 Jul;19(7):1300–1310.
   PubMed Web of Science ®Google Scholar
• Yanda MK, Cha B, Cebotaru CV, et al. Pharmacological reversal of renal cysts from secretion to absorption suggests a potential therapeutic strategy for managing autosomal dominant polycystic kidney disease. J Biol Chem. 2019 Nov 8;294(45):17090–17104.
   PubMed Web of Science ®Google Scholar
• Cabrita I, Kraus A, Scholz JK, et al. Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo. Nat Commun. 2020 Aug 28;11(1):4320.
   PubMed Web of Science ®Google Scholar
• Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, et al. Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease. PPAR Res. 2010;2010:274376.
   PubMedGoogle Scholar
• Nofziger C, Brown KK, Smith CD, et al. PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line. Am J Physiol Renal Physiol. 2009 Jul;297(1):F55–62.
   PubMed Web of Science ®Google Scholar
• Yoshihara D, Kurahashi H, Morita M, et al. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2011 Feb;300(2):F465–74.
   PubMed Web of Science ®Google Scholar
• Muto S, Aiba A, Saito Y, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 2002 Jul 15;11(15):1731–1742.
   PubMed Web of Science ®Google Scholar
• Dai B, Liu YW, Mei CL, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin sci. 2010 Oct;119(7–8):323–333.
   Web of Science ®Google Scholar
• Kanhai AA, Bange H, Verburg L, et al. Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective. Sci Rep-UK. 2020 Feb 3;10(1):1672.
   Web of Science ®Google Scholar
• Klawitter J, Zafar I, Klawitter J, et al. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol. 2013 Jul 31;14:165.
   PubMed Web of Science ®Google Scholar
• van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transpl. 2001 Nov;16(11):2152–2157.
   PubMed Web of Science ®Google Scholar
• Capuano I, Riccio E, Caccavallo S, et al. ADPKD and metformin: from bench to bedside. Clin Exp Nephrol. 2019 Nov;23(11):1341–1342.
   PubMed Web of Science ®Google Scholar
• Natoli TA, Smith LA, Rogers KA, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med. 2010 Jul;16(7):788–792.
   PubMed Web of Science ®Google Scholar
• Perrone RD, Hariri A, Minini P, et al. The STAGED-PKD 2-stage adaptive study with a patient enrichment strategy and treatment effect modeling for improved study design efficiency in patients with ADPKD. Kidney Med. 2022 Oct;4(10):100538.
   PubMedGoogle Scholar
• Sankaran D, Bankovic-Calic N, Ogborn MR, et al. Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han: SPRD-cy rats with inherited kidney disease. Am J Physiol-Renal. 2007 Sep;293(3):F821–F830.
   PubMed Web of Science ®Google Scholar
• Monirujjaman M, Aukema HM. Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2(WS25/-) mouse model of autosomal dominant polycystic kidney disease. J Nephrol. 2019 Jun;32(3):401–409.
   PubMed Web of Science ®Google Scholar
• Ibrahim NH, Gregoire M, Devassy JG, et al. Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease. Prostaglandins Other Lipid Mediat. 2015 Jan-Mar;116-117:19–25.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Devassy JG, Gabbs M, et al. Dietary flax oil rich in alpha-linolenic acid reduces renal disease and oxylipin abnormalities, including formation of docosahexaenoic acid derived oxylipins in the CD1-pcy/pcy mouse model of nephronophthisis. Prostaglandins Leukot Essent Fatty Acids. 2015 Mar;94:83–89.
   PubMed Web of Science ®Google Scholar
• Celentano S, Capolongo G, Pollastro RM. Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease?. G Ital Nefrol. 2019 Sep 24;36(5):2019-vol5. Italian. PMID: 31580543.
   PubMedGoogle Scholar
• Rossing P, Block GA, Chin MP, et al. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. Kidney Int. 2019 Oct;96(4):1030–1036.
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in Type 2 diabetes and Stage 4 chronic kidney disease. New Engl J Med. 2013 Dec 26;369(26):2492–2503.
   PubMed Web of Science ®Google Scholar
• Ito M, Tanaka T, Nangaku M. Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. Curr Opin Nephrol Hy. 2020 Jan;29(1):128–135.
   PubMed Web of Science ®Google Scholar
• Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol. 2008 Sep;19(9):1659–1662.
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5466–5471.
   PubMed Web of Science ®Google Scholar
• Tao YX, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005 Jan;16(1):46–51.
   PubMed Web of Science ®Google Scholar
• Li A, Fan S, Xu YC, et al. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. J Cell Mol Med. 2017 Aug;21(8):1619–1635.
   PubMed Web of Science ®Google Scholar
• Tobin JL, Beales PL. Restoration of renal function in zebrafish models of ciliopathies. Pediatr Nephrol. 2008 Nov;23(11):2095–2099.
   PubMed Web of Science ®Google Scholar
• Zafar I, Ravichandran K, Belibi FA, et al. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int. 2010 Oct;78(8):754–761.
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Piontek KB, Germino GG, et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010 Mar;21(3):489–497.
   PubMed Web of Science ®Google Scholar
• e Zeeuw D, Akizawa T, Audhya P, et al. BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013 Dec 26;369(26):2492–503.
   PubMed Web of Science ®Google Scholar
• Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol. 2008 Mar;19(3):631–638.
   PubMed Web of Science ®Google Scholar
• Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010 Aug 26;363(9):820–829.
   PubMed Web of Science ®Google Scholar
• Shillingford JM, Leamon CP, Vlahov IR, et al. Folate-conjugated rapamycin slows progression of polycystic kidney disease. J Am Soc Nephrol. 2012 Oct;23(10):1674–1681.
   PubMed Web of Science ®Google Scholar
• Holditch SJ, Brown CN, Atwood DJ, et al. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 Jul 1;317(1):F187–F196.
   PubMed Web of Science ®Google Scholar
• Wu M, Wahl PR, Le Hir M, et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press R. 2007;30(4):253–259.
   PubMed Web of Science ®Google Scholar
• Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010 Aug 26;363(9):830–840.
   PubMed Web of Science ®Google Scholar
• Sweeney WE, Chen YG, Nakanishi K, et al. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000 Jan;57(1):33–40.
   PubMed Web of Science ®Google Scholar
• Chang MY, A CMO. Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2018 Aug 1;33(8):1310–1316.
   PubMed Web of Science ®Google Scholar
• Tesar V, Ciechanowski K, Pei Y, et al. Bosutinib versus placebo for autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2017 Nov;28(11):3404–3413.
   PubMed Web of Science ®Google Scholar
• Sweeney WE Jr., von Vigier RO, Frost P, et al. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol. 2008 Jul;19(7):1331–1341.
   PubMed Web of Science ®Google Scholar
• Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol-Cell Ph. 2011 Aug;301(2):C522–C529.
   PubMed Web of Science ®Google Scholar
• Torres VE, Sweeney WE, Wang XF, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han : SPRD rats. Kidney Int. 2003 Nov;64(5):1573–1579.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Reif GA, Calvet JP, et al. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol-Renal. 2010 Nov;299(5):F944–F951.
   PubMed Web of Science ®Google Scholar
• Calvet JP. MEK inhibition holds promise for polycystic kidney disease. J Am Soc Nephrol. 2006 Jun;17(6):1498–1500.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Sugiyama N, Tanimura S, et al. ERK regulates renal cell proliferation and renal cyst expansion in inv mutant mice. Acta Histochem Cytochem. 2009 Apr 28;42(2):39–45.
   PubMed Web of Science ®Google Scholar
• Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013 Nov 2;382(9903):1485–1495.
   PubMed Web of Science ®Google Scholar
• Meijer E, Visser FW, van Aerts RMM, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: The DIPAK 1 randomized clinical trial. JAMA. 2018 Nov 20;320(19):2010–2019.
   PubMed Web of Science ®Google Scholar
• Treille S, Bailly JM, Van Cauter J, et al. The use of lanreotide in polycystic kidney disease: a single-centre experience. Case Rep Nephrol Urol. 2014 Jan;4(1):18–24.
   PubMedGoogle Scholar
• Gevers TJ, Hol JC, Monshouwer R, et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Liver Int. 2015 May;35(5):1607–1614.
   PubMed Web of Science ®Google Scholar
• Masyuk TV, Radtke BN, Stroope AJ, et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology. 2013 Jul;58(1):409–421.
   PubMed Web of Science ®Google Scholar
• Perico N, Ruggenenti P, Perna A, et al. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLOS Med. 2019 Apr;16(4):e1002777.
   PubMed Web of Science ®Google Scholar
• Trillini M, Caroli A, Perico N, et al. Effects of octreotide-long-acting release added-on tolvaptan in patients with autosomal dominant polycystic kidney disease: pilot, randomized, placebo-controlled, cross-over trial. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):223–233.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Hurd T, Hildebrandt F. 3D spheroid defects in NPHP knockdown cells are rescued by the somatostatin receptor agonist octreotide. Am J Physiol-Renal. 2012 Oct;303(8):F1225–F1229.
   PubMed Web of Science ®Google Scholar
• Hogan MC, Chamberlin JA, Vaughan LE, et al. Pansomatostatin agonist pasireotide long-acting release for patients with autosomal dominant polycystic kidney or liver disease with severe liver involvement: a randomized clinical trial. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1267–1278.
   PubMed Web of Science ®Google Scholar
• Takiar V, Nishio S, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2462–2467.
   PubMed Web of Science ®Google Scholar
• Chang MY, Ma TL, Hung CC, et al. Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci Rep-UK. 2017 Aug 2;7(1):7161.
   PubMed Web of Science ®Google Scholar
• Seliger SL, Abebe KZ, Hallows KR, et al. A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease. Am J Nephrol. 2018;47(5):352–360.
   PubMed Web of Science ®Google Scholar
• Sorohan BM, Ismail G, Andronesi A, et al. A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2019 Jul 23;20(1):276.
   Web of Science ®Google Scholar
• Pisani A, Riccio E, Bruzzese D, et al. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?. BMC Nephrol. 2018 Oct 22;19(1):282.
   PubMedGoogle Scholar
• Leonhard WN, Song XW, Kanhai AA, et al. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine. 2019 Sep;47:436–445.
   PubMed Web of Science ®Google Scholar
• Rowe I, Chiaravalli M, Mannella V, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013 Apr;19(4):488–493.
   PubMed Web of Science ®Google Scholar
• Bracken C, Beauverger P, Duclos O, et al. CaMKII as a pathological mediator of ER stress, oxidative stress, and mitochondrial dysfunction in a murine model of nephronophthisis. Am J Physiol-Renal. 2016 Jun 1;310(11):F1414–F1422.
   PubMed Web of Science ®Google Scholar
• Garcia H, Serafin AS, Silbermann F, et al. Agonists of prostaglandin E(2) receptors as potential first in class treatment for nephronophthisis and related ciliopathies. Proc Natl Acad Sci U S A. 2022 May 3;119(18):e2115960119.
   PubMed Web of Science ®Google Scholar
• Tao Y, Kim J, Yin Y, et al. VEGF receptor inhibition slows the progression of polycystic kidney disease. Kidney Int. 2007 Dec;72(11):1358–1366.
   PubMed Web of Science ®Google Scholar
• Tran PV, Talbott GC, Turbe-Doan A, et al. Downregulating hedgehog signaling reduces renal cystogenic potential of mouse models. J Am Soc Nephrol. 2014 Oct;25(10):2201–2212.
   PubMed Web of Science ®Google Scholar
• Yanda MK, Liu Q, Cebotaru V, et al. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca(2+) in knock-out mouse models of polycystic kidney disease. J Biol Chem. 2017 Oct 27;292(43):17897–17908.
   PubMed Web of Science ®Google Scholar
• Cebotaru L, Liu QG, Yanda MK, et al. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney Int. 2016 Jul;90(1):90–99.
   PubMed Web of Science ®Google Scholar
• Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. P Natl Acad Sci USA. 2009 Dec 22;106(51):21819–21824.
   PubMed Web of Science ®Google Scholar
• Fan LX, Li XJ, Magenheimer B, et al. Inhibition of histone deacetylases targets the transcription regulator Id2 to attenuate cystic epithelial cell proliferation. Kidney Int. 2012 Jan;81(1):76–85.
   PubMed Web of Science ®Google Scholar
• Zhou X, Fan LX, Sweeney WE, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J Clin Investig. 2013 Jul;123(7):3084–3098.
   PubMed Web of Science ®Google Scholar
• Nikonova AS, Deneka AY, Kiseleva AA, et al. Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J. 2018 May;32(5):2735–2746.
   PubMed Web of Science ®Google Scholar
• Seeger-Nukpezah T, Proia DA, Egleston BL, et al. Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12786–12791.
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Smith LA, Klinger KW, et al. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature. 2006 Dec 14;444(7121):949–952.
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Moreno SE, Natoli TA, et al. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 2012 Nov 1;11(21):4040–4046.
   PubMed Web of Science ®Google Scholar
• Husson H, Moreno S, Smith LA, et al. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Hum Mol Genet. 2016 Jun 1;25(11):2245–2255.
   PubMed Web of Science ®Google Scholar
• Airik R, Airik M, Schueler M, et al. Roscovitine blocks collecting duct cyst growth in Cep164-deficient kidneys. Kidney Int. 2019 Aug;96(2):320–326.
   PubMed Web of Science ®Google Scholar
• Slaats GG, Saldivar JC, Bacal J, et al. DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome. J Clin Investig. 2015 Sep;125(9):3657–3666.
   PubMed Web of Science ®Google Scholar
• Masyuk TV, Radtke BN, Stroope AJ, et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology. 2012 Mar;142(3):622–633 e4.
   PubMed Web of Science ®Google Scholar
• Yheskel M, Lakhia R, Cobo-Stark P, et al. Anti-microRNA screen uncovers miR-17 family within miR-17 similar to 92 cluster as the primary driver of kidney cyst growth. Sci Rep-UK. 2019 Feb 13;9:1920.
   PubMed Web of Science ®Google Scholar
• Lee EC, Valencia T, Allerson C, et al. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148.
   PubMedGoogle Scholar
• Zhou JX, Li X. Non-Coding RNAs in Hereditary Kidney Disorders. Int J Mol Sci. 2021 Mar 16;22(6):3014.
   Web of Science ®Google Scholar
• Ramsbottom SA, Molinari E, Srivastava S, et al. Targeted exon skipping of a CEP290 mutation rescues Joubert syndrome phenotypes in vitro and in a murine model. Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12489–12494.
   PubMed Web of Science ®Google Scholar
• Ramsbottom SA, Thelwall PE, Wood KM, et al. Mouse genetics reveals Barttin as a genetic modifier of Joubert syndrome. Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1113–1118.
   PubMed Web of Science ®Google Scholar
• Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Int. 2005 Nov;68(5):2405–2418.
   PubMed Web of Science ®Google Scholar
• Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003 Oct;9(10):1323–1326.
   PubMed Web of Science ®Google Scholar
• Endo M, Katayama K, Matsuo H, et al. Role of liver transplantation in tolvaptan-associated acute liver failure. Kidney Int Rep. 2019 Nov;4(11):1653–1657.
   PubMed Web of Science ®Google Scholar
• Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations. Int J Nephrol Renov. 2018;11:41–51.
   PubMed Web of Science ®Google Scholar
• Di Mise A, Venneri M, Ranieri M, et al. Lixivaptan, a new generation diuretic, counteracts vasopressin-induced Aquaporin-2 trafficking and function in renal collecting duct cells. Int J Mol Sci. 2019 Dec 26;21(1):183.
   PubMed Web of Science ®Google Scholar
• Wang X, Constans MM, Chebib FT, et al. Effect of a Vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model. Am J Nephrol. 2019;49(6):487–493.
   PubMed Web of Science ®Google Scholar
• Hanaoka K, Devuyst O, Schwiebert EM, et al. A role for CFTR in human autosomal dominant polycystic kidney disease. Am J physiol. 1996 Jan;270(1 Pt 1):C389–99.
   PubMedGoogle Scholar
• Ye M, Grantham JJ. The Secretion of fluid by renal cysts from patients with autosomal-dominant polycystic kidney-disease. New Engl J Med. 1993 Jul 29;329(5):310–313.
   PubMed Web of Science ®Google Scholar
• Yanda MK, Cebotaru L. VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation. FASEB J. 2021 Nov;35(11):e21987.
   PubMed Web of Science ®Google Scholar
• Seo Y, Kim J, Chang J, et al. Synthesis and biological evaluation of novel Ani9 derivatives as potent and selective ANO1 inhibitors. Eur J Med Chem. 2018 Dec 5;160:245–255.
   PubMed Web of Science ®Google Scholar
• Miner K, Labitzke K, Liu BX, et al. Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol. 2019 Feb 14;10:51.
   PubMed Web of Science ®Google Scholar
• Lakhia R. The role of PPAR alpha in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hy. 2020 Jul;29(4):432–438.
   PubMed Web of Science ®Google Scholar
• Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation. 2006 Dec 12;114(24):2655–2662.
   PubMed Web of Science ®Google Scholar
• Natoli TA, Modur V, Ibraghimov-Beskrovnaya O. Glycosphingolipid metabolism and polycystic kidney disease. Cell Signal. 2020 May;69:109526.
   PubMed Web of Science ®Google Scholar
• Swenson-Fields KI, Vivian CJ, Salah SM, et al. Macrophages promote polycystic kidney disease progression. Kidney Int. 2013 May;83(5):855–864.
   PubMed Web of Science ®Google Scholar
• Marra AN, Adeeb BD, Chambers BE, et al. Prostaglandin signaling regulates renal multiciliated cell specification and maturation. Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8409–8418.
   PubMed Web of Science ®Google Scholar
• Zhang JQJ, Saravanabavan S, Munt A, et al. The role of DNA damage as a therapeutic target in autosomal dominant polycystic kidney disease. Expert Rev Mol Med. 2019 Nov 26;21:e6.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Lysecki C, Reid A, et al. Renal cyclooxygenase products are higher and lipoxygenase products are lower in early disease in the pcy mouse model of adolescent nephronophthisis. Lipids. 2014 Jan;49(1):39–47.
   PubMed Web of Science ®Google Scholar
• Martin-Hurtado A, Martin-Morales R, Robledinos-Anton N, et al. NRF2-dependent gene expression promotes ciliogenesis and Hedgehog signaling. Sci Rep. 2019 Sep 25;9(1):13896.
   PubMedGoogle Scholar
• Liu P, Dodson M, Fang D, et al. NRF2 negatively regulates primary ciliogenesis and hedgehog signaling. PLoS Biol. 2020 Feb;18(2):e3000620.
   PubMed Web of Science ®Google Scholar
• Viau A, Bienaime F, Lukas K, et al. Cilia-localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney. EMBO J. 2018 Aug 1;37(15):e98615.
   PubMed Web of Science ®Google Scholar
• Pema M, Drusian L, Chiaravalli M, et al. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex. Nat Commun. 2016 Mar 2;7:10786.
   PubMed Web of Science ®Google Scholar
• Lai YD, Jiang Y. Reciprocal regulation between primary cilia and mTORC1. Genes-Basel. 2020 Jun 26;11(6):711.
   Web of Science ®Google Scholar
• Shao L, El-Jouni W, Kong F, et al. Genetic reduction of cilium length by targeting intraflagellar transport 88 protein impedes kidney and liver cyst formation in mouse models of autosomal polycystic kidney disease. Kidney Int. 2020 Nov;98(5):1225–1241.
   PubMed Web of Science ®Google Scholar
• Lin CH, Chao CT, Wu MY, et al. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis. Int Urol Nephrol. 2019 Nov;51(11):2015–2025.
   PubMed Web of Science ®Google Scholar
• Herzig S, Shaw, RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018 Feb;19(2):121–135.
   PubMed Web of Science ®Google Scholar
• Padovano V, Podrini C, Boletta A, et al. Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat rev Nephrol. 2018 Nov;14(11):678–687.
   PubMed Web of Science ®Google Scholar
• Podrini C, Cassina L, Boletta A. Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell Signal. 2020 Mar;67:109495.
   PubMed Web of Science ®Google Scholar
• Ishimoto Y, Inagi R, Yoshihara D, et al. Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol Cell Biol. 2017 Dec 15;37(24):e0033717.
   PubMed Web of Science ®Google Scholar
• Anderson K, Wherle L, Park M, et al. Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies. Am Health Drug Benefits. 2014 Jun;7(4):231–235.
   PubMedGoogle Scholar
• Haws RM, Gordon G, Han JC, et al. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alstrom syndrome: Phase 3 trial design. Contemp Clin Trials Commun. 2021 Jun;22:100780.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ebihara I, Nagaoka I, et al. Growth factor gene expression in kidney of murine polycystic kidney disease. J Am Soc Nephrol. 1993 Jan;3(7):1378–1386.
   PubMed Web of Science ®Google Scholar
• Gunther T, Tulipano G, Dournaud P, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev. 2018 Oct;70(4):763–835.
   PubMed Web of Science ®Google Scholar
• Law SF, Manning D, Reisine T. Identification of the subunits of GTP-binding proteins coupled to somatostatin receptors. J Biol Chem. 1991 Sep 25;266(27):17885–17897.
   PubMed Web of Science ®Google Scholar
• Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004 Apr;102(1):61–85.
   PubMed Web of Science ®Google Scholar
• Ferjoux G, Bousquet C, Cordelier P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 2000 May-Aug;94(3–4):205–210.
   PubMedGoogle Scholar
• Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol. 2014 Jan;25(1):18–32.
   PubMed Web of Science ®Google Scholar
• Sun L, Yu CY, Mackey LV, et al. Lanreotide and its potential applications in polycystic kidney and liver diseases. Curr Top Med Chem. 2015;16(2):133–140.
   PubMed Web of Science ®Google Scholar
• Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens. 2009 Mar;18(2):99–106.
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Hurd T, Hildebrandt F. 3D spheroid defects in NPHP knockdown cells are rescued by the somatostatin receptor agonist octreotide. Am J Physiol Renal Physiol. 2012 Oct 15;303(8):F1225–9.
   PubMed Web of Science ®Google Scholar
• Reed BY, Masoumi A, Elhassan E, et al. Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011 Jan;79(1):128–134.
   PubMed Web of Science ®Google Scholar
• Yu F, Ran J, Zhou J. Ciliopathies: does HDAC6 represent a new therapeutic target?. Trends Pharmacol Sci. 2016 Feb;37(2):114–119.
   PubMed Web of Science ®Google Scholar
• Kovacs JJ, Murphy PJM, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005 May 27;18(5):601–607.
   PubMed Web of Science ®Google Scholar
• Prodromou NV, Thompson CL, Osborn DP, et al. Heat shock induces rapid resorption of primary cilia. J Cell Sci. 2012 Sep 15;125(Pt 18):4297–4305.
   PubMed Web of Science ®Google Scholar
• Chun P. Therapeutic effects of histone deacetylase inhibitors on kidney disease. Arch Pharm Res. 2018 Feb;41(2):162–183.
   PubMed Web of Science ®Google Scholar
• Li B, Rauhauser AA, Dai J, et al. Increased hedgehog signaling in postnatal kidney results in aberrant activation of nephron developmental programs. Hum Mol Genet. 2011 Nov 1;20(21):4155–4166.
   PubMed Web of Science ®Google Scholar
• Kopinke D, Norris AM, Mukhopadhyay S. Developmental and regenerative paradigms of cilia regulated hedgehog signaling. Semin Cell Dev Biol. 2021 Feb;110:89–103.
   PubMed Web of Science ®Google Scholar
• Ruiz-Perez VL, Blair HJ, Rodriguez-Andres ME, et al. Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia. Development. 2007 Aug 15;134(16):2903–2912.
   PubMed Web of Science ®Google Scholar
• Aguilar A, Meunier A, Strehl L, et al. Analysis of human samples reveals impaired SHH-dependent cerebellar development in Joubert syndrome/Meckel syndrome. P Natl Acad Sci USA. 2012 Oct 16;109(42):16951–16956.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Nagao S, Kasahara M, et al. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis. 1997 Nov;30(5):703–709.
   PubMed Web of Science ®Google Scholar
• Smith LA, Bukanov NO, Husson H, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: Insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol. 2006 Oct;17(10):2821–2831.
   PubMed Web of Science ®Google Scholar
• Wallace DP. Cyclic AMP-mediated cyst expansion. BBA-Mol Basis Dis. 2011 Oct;1812(10):1291–1300.
   PubMed Web of Science ®Google Scholar
• Calvet JP. The Role of Calcium and Cyclic AMP in PKD. In: Li X, editor. Polycystic kidney disease. Brisbane (AU): Codon Publications; 2015. Nov. Chapter 8.
   Google Scholar
• Chen NX, Moe SM, Eggleston-Gulyas T, et al. Calcimimetics inhibit renal pathology in rodent nephronophthisis. Kidney Int. 2011 Sep;80(6):612–619.
   PubMed Web of Science ®Google Scholar
• Simons M, Gloy J, Ganner A, et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet. 2005 May;37(5):537–543.
   PubMed Web of Science ®Google Scholar
• Bergmann C, Fliegauf M, Bruchle NO, et al. Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. Am J Hum Genet. 2008 Apr;82(4):959–970.
   PubMed Web of Science ®Google Scholar
• Wang Q, Cobo-Stark P, Patel V, et al. Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease. Kidney Int. 2018 Feb;93(2):403–415.
   PubMed Web of Science ®Google Scholar
• Schueler M, Braun DA, Chandrasekar G, et al. DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling. Am J Hum Genet. 2015 Jan 8;96(1):81–92.
   PubMed Web of Science ®Google Scholar
• Habbig S, Bartram MP, Muller RU, et al. NPHP4, a cilia-associated protein, negatively regulates the hippo pathway. J Cell Bio. 2011 May 16;193(4):633–642.
   PubMed Web of Science ®Google Scholar
• Habbig S, Bartram MP, Sagmuller JG, et al. The ciliopathy disease protein NPHP9 promotes nuclear delivery and activation of the oncogenic transcriptional regulator TAZ. Hum Mol Genet. 2012 Dec 15;21(26):5528–5538.
   PubMed Web of Science ®Google Scholar
• Frank V, Habbig S, Bartram MP, et al. Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression. Hum Mol Genet. 2013 Jun 1;22(11):2177–2185.
   PubMed Web of Science ®Google Scholar
• Grampa V, Delous M, Zaidan M, et al. Novel NEK8 mutations cause severe syndromic renal cystic dysplasia through YAP dysregulation. PLoS Genet. 2016 Mar;12(3):e1005894.
   PubMed Web of Science ®Google Scholar
• Muller RU, Schermer B. Hippo signaling-a central player in cystic kidney disease?. Pediatr Nephrol. 2020 Jul;35(7):1143–1152.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang L, Zhang Y, et al. Tubule-specific Mst1/2 deficiency induces CKD via YAP and Non-YAP mechanisms. J Am Soc Nephrol. 2020 May;31(5):946–961.
   PubMed Web of Science ®Google Scholar
• Szeto SG, Narimatsu M, Lu ML, et al. YAP/TAZ are mechanoregulators of TGF-beta-smad signaling and renal fibrogenesis. J Am Soc Nephrol. 2016 Oct;27(10):3117–3128.
   PubMed Web of Science ®Google Scholar
• Rees S, Kittikulsuth W, Roos K, et al. Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease. J Am Soc Nephrol. 2014 Feb;25(2):232–237.
   PubMed Web of Science ®Google Scholar
• Omar F, Findlay JE, Carfray G, et al. Small-molecule allosteric activators of PDE4 long form cyclic AMP phosphodiesterases. Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13320–13329.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Lin JR, Vannier JB, et al. NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. Mol Cell. 2013 Aug 22;51(4):423–439.
   PubMed Web of Science ®Google Scholar
• Airik R, Slaats GG, Guo Z, et al. Renal-retinal ciliopathy gene Sdccag8 regulates DNA damage response signaling. J Am Soc Nephrol. 2014 Nov;25(11):2573–2583.
   PubMed Web of Science ®Google Scholar
• Pan YR, Lee EY. UV-dependent interaction between Cep164 and XPA mediates localization of Cep164 at sites of DNA damage and UV sensitivity. Cell Cycle. 2009 Feb 15;8(4):655–664.
   PubMed Web of Science ®Google Scholar
• Hoff S, Epting D, Falk N, et al. The nucleoside-diphosphate kinase NME3 associates with nephronophthisis proteins and is required for ciliary function during renal development. J Biol Chem. 2018 Sep 28;293(39):15243–15255.
   PubMed Web of Science ®Google Scholar
• Daly OM, Gaboriau D, Karakaya K, et al. CEP164-null cells generated by genome editing show a ciliation defect with intact DNA repair capacity. J Cell Sci. 2016 May 1;129(9):1769–1774.
   PubMed Web of Science ®Google Scholar
• Ramalingam H, Yheskel M, Patel V. Modulation of polycystic kidney disease by non-coding RNAs. Cell Signal. 2020 Jul;71:109548. DOI:10.1016/j.cellsig.2020.109548
   Web of Science ®Google Scholar
• Hajarnis S, Lakhia R, Yheskel M, et al. microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat Commun. 2017 Feb 16;8:14395.
   PubMed Web of Science ®Google Scholar
• Kuo IY, Brill AL, Lemos FO, et al. Polycystin 2 regulates mitochondrial Ca(2+) signaling, bioenergetics, and dynamics through mitofusin 2. Sci Signal. 2019 May 7;12(580):eaat7397.
   PubMed Web of Science ®Google Scholar
• Gomez IG, MacKenna DA, Johnson BG, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Investig. 2015 Jan;125(1):141–156.
   PubMed Web of Science ®Google Scholar
• Yamamura T, Horinouchi T, Adachi T, et al. Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5. Nat Commun. 2020 Jun 2;11(1):2777.
   Web of Science ®Google Scholar
• Xue K, MacLaren RE. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opin Investig Drugs. 2020 Oct;29(10):1163–1170.
   PubMed Web of Science ®Google Scholar
• Duijkers L, van den Born LI, Neidhardt J, et al. Antisense oligonucleotide-based splicing correction in individuals with Leber congenital amaurosis due to compound heterozygosity for the c.2991+1655A>G mutation in CEP290. Int J Mol Sci. 2018 Mar 7;19(3):753.
   PubMed Web of Science ®Google Scholar
• Barny I, Perrault I, Michel C, et al. Basal exon skipping and nonsense-associated altered splicing allows bypassing complete CEP290 loss-of-function in individuals with unusually mild retinal disease. Hum Mol Genet. 2018 Aug 1;27(15):2689–2702.
   PubMedGoogle Scholar
• Barny I, Perrault I, Michel C, et al. AON-mediated exon skipping to bypass protein truncation in retinal dystrophies due to the recurrent CEP290 c.4723A > T mutation fact or fiction?. Genes-Basel. 2019 May;10(5):368.
   PubMed Web of Science ®Google Scholar
• Tayfur AC, Besbas N, Bilginer Y, et al. Follow-up of patients with juvenile nephronophthisis after renal transplantation: a single center experience. Transplant Proc. 2011 Apr;43(3):847–849.
   PubMed Web of Science ®Google Scholar
• Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020 Mar;29(2):190–198.
   PubMed Web of Science ®Google Scholar
• Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018 Oct;61(10):2108–2117.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Dapagliflozin: a review in Type 2 diabetes. Drugs. 2019 Jul;79(10):1135–1146.
   PubMed Web of Science ®Google Scholar
• Marcath LA. Finerenone. Clin Diabetes. 2021 Jul;39(3):331–332.
   PubMedGoogle Scholar
• Afsar B, Afsar RE, Demiray A, et al. Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction. Clin Kidney J. 2022 Jul;15(7):1275–1283.
   PubMed Web of Science ®Google Scholar
• Afsar B, Hornum M, Afsar RE, et al. Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion. 2021 May;58:72–82.
   PubMed Web of Science ®Google Scholar
• Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021 Apr 6;33(4):732–739.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–2229.
   PubMed Web of Science ®Google Scholar
• Rubel D, Boulanger J, Craciun F, et al. Anti-microRNA-21 therapy on top of ace inhibition delays renal failure in Alport syndrome mouse models. Cells. 2022 Feb 9;11(4):594.
   PubMed Web of Science ®Google Scholar
• Chavez E, Rodriguez J, Drexler Y, et al. Novel therapies for Alport syndrome. Front Med. 2022;9:848389.
   PubMed Web of Science ®Google Scholar
• Ramos AM, Gonzalez-Guerrero C, Sanz A, et al. Designing drugs that combat kidney damage. Expert Opin Drug Dis. 2015 May;10(5):541–556.
   PubMed Web of Science ®Google Scholar